Adaptive Biotechnologies Corp vs Medtronic PLC — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Medtronic PLC trades at $90.25 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 28.7× Adaptive Biotechnologies Corp's market cap, and Medtronic PLC pays a 3.18% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MDT | |
|---|---|---|
Market Cap | $4.04B | $116.07B |
Sector | Health | Health |
52-Week High | $25.45 | $105.35 |
52-Week Low | $12.30 | $73.75 |
Enterprise Value | $4.10B | $134.82B |
Dividend Yield | — | 3.18% |
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →